CYP19A1 and breast cancer: Among the biomarkers associated with frailty syndrome in breast cancer patients, the best profile is represented by the aromatase activity index, which showed a good sensitivity of 87% and a moderate specificity of 54.2% to discriminate between frail and non-frail patients.